KERYX BIOPHARMACEUTICALS INC Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013
Revenues:
Net U.S. Auryxia product sales
License revenue
Total revenues
Costs and expenses:
Non-cash compensation
Other research and development
Cost of goods sold
License expense
Research and development
Other general and administrative
Total general and administrative
Selling, general and administrative
Total costs and expenses

Operating loss
Other (expense) income:
Amortization of debt discount
Other (expense) income, net
Total other expense:
Loss before income taxes
Income tax (benefit) expense
Loss from continuing operations
Net loss
Continuing operations
Basic and diluted net loss per common share (USD per share)
Weighted average shares used in computing basic and diluted net loss per common share (in shares)

Comments